Sort
10,766 grants matching “checkpoint inhibitor”
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2021 · NS
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2019 · NS
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2020 · NS
Applying deep learning to predict T cell receptor binding specificity of neoantigens and response to checkpoint inhibitors
$378,897Tao Wang · Ut Southwestern Medical Center · R01 · FY2021 · CA
A Pathway for Necrotic Cell Death
$378,867David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA
A Pathway for Necrotic Cell Death
$378,867David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2023 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma
$378,856Amaia Lujambio · Icahn School Of Medicine At Mount Sinai · R37 · FY2023 · CA
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma
$378,841James Kim · Ut Southwestern Medical Center · R01 · FY2022 · CA
Project 2: Targeting DNA replication in BRCA-associated breast cancer
$378,763Bing Xia · Rutgers Biomedical And Health Sciences · P01 · FY2025 · CA
Regulation of the Development of Trypanosoma brucei
$378,750University Of California San Francisco · R01 · FY2005 · AI
Regulation of the Development of Trypanosoma brucei
$378,750University Of California San Francisco · R01 · FY2004 · AI
Genetic regulation of genome stability in yeast
$378,690Thomas D Petes · Duke University · R01 · FY2008 · GM
Genetic regulation of genome stability in yeast
$378,690Thomas D Petes · Duke University · R01 · FY2009 · GM
Tumor microenvironment-dependent therapy resistance
$378,600Shahab Asgharzadeh · Children'S Hosp Of Philadelphia · P01 · FY2024 · CA
Targeting heat shock factor 1 (HSF1) to increase tumor infiltrating lymphocytes in metastatic breast cancer.
$378,444Richard L Carpenter · Indiana University Indianapolis · R01 · FY2025 · CA
Core B: Computational
$378,433Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2017 · AI
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
$378,430Kapil N. Bhalla · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Personalized targeting of anti-apoptosis pathways to overcome therapeutic resistance in melanoma
$378,415Michael Davies · Wistar Institute · U54 · FY2024 · CA
Rare Central Nervous System Cancers Initiative
$378,413Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Brain Tumor Immunotherapy
$378,413Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$378,369Robert M Prins · University Of California Los Angeles · P50 · FY2023 · CA
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$378,348Everett Stone · University Of Texas At Austin · R01 · FY2021 · CA
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$378,315Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2023 · CA
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma
$378,300Carl J Koschmann · University Of Michigan At Ann Arbor · R01 · FY2024 · NS
Gene expression signature based screening in Ewing sarcoma
$378,253David J Gordon · University Of Iowa · R37 · FY2020 · CA